Hyperhomocysteinemia An Additional Risk Factor in White Coat Hypertension

The association between homocysteine and sustained hypertension (HT) has been studied. The aim of this study was to assess homocysteine levels in white coat hypertension (WCH) as an indicator of increased risk in the development of cardiovascular diseases. WCH was defined as clinical hypertension an...

Full description

Saved in:
Bibliographic Details
Published inInternational Heart Journal Vol. 46; no. 2; pp. 245 - 254
Main Authors Çurgunlu, Asll, Aydin, Seval, Ertürk, Nurver, Vehid, Suphi, Uzun, Hafize, Karter, Yesari, Kutlu, Ayse, Erdine, Serap, Simsek, Gönül, Öztürk, Esin
Format Journal Article
LanguageEnglish
Published Japan International Heart Journal Association 01.03.2005
Subjects
Online AccessGet full text
ISSN1349-2365
1349-3299
DOI10.1536/ihj.46.245

Cover

Abstract The association between homocysteine and sustained hypertension (HT) has been studied. The aim of this study was to assess homocysteine levels in white coat hypertension (WCH) as an indicator of increased risk in the development of cardiovascular diseases. WCH was defined as clinical hypertension and a daytime ambulatory blood pressure of < 135/85 mmHg. Plasma levels of homocysteine were determined in patients with WCH, hypertension, and normotension (NT). The study group included 100 subjects, 33 with WCH (16 males, 17 females) aged 49.1 ± 1.9; 35 sustained hypertensives (17 males,18 females) aged 48.5 ± 1.7 and 32 normotensive control subjects (15 males, 17 females) aged 48.8 ± 2.2. The subjects were matched for age, gender, and body mass index. Patients with a smoking habit, dyslipidemia, or diabetes mellitus were not included in the study. Homocysteine levels were analyzed by ELISA. Plasma homocysteine levels were significantly higher in the WCH group compared to the controls (12.32 ± 1.07 versus 5.35 ± 1.38 μmol/L; P < 0.001) and the WCH group had significantly lower homocysteine values than the hypertensives (19.03 ± 0.76 μmol/L P < 0.001). Total cholesterol and tri-glycerides were not different among the groups. There were no statistically significant differences in urinary albumin excretion (UAE) or creatinine clearence between the three groups. Hypertensive retinopathy was observed in the WCH group, but was less severe and less frequent compared to HTs. LVMI was greater in the WCH group compared to the NTs, but significantly less than HTs. The data demonstrate that WCH is associated with high levels of homocysteine. The increase in homocysteine level in WCH is not as high as in SHT. Since an elevated plasma homocysteine level is a strong risk factor for coronary artery disease and there was target organ damage in our WCH group, we conclude that WCH should not be considered to be an innocent trait.
AbstractList The association between homocysteine and sustained hypertension (HT) has been studied. The aim of this study was to assess homocysteine levels in white coat hypertension (WCH) as an indicator of increased risk in the development of cardiovascular diseases. WCH was defined as clinical hypertension and a daytime ambulatory blood pressure of < 135/85 mmHg. Plasma levels of homocysteine were determined in patients with WCH, hypertension, and normotension (NT). The study group included 100 subjects, 33 with WCH (16 males, 17 females) aged 49.1 +/- 1.9; 35 sustained hypertensives (17 males,18 females) aged 48.5 +/- 1.7 and 32 normotensive control subjects (15 males, 17 females) aged 48.8 +/- 2.2. The subjects were matched for age, gender, and body mass index. Patients with a smoking habit, dyslipidemia, or diabetes mellitus were not included in the study. Homocysteine levels were analyzed by ELISA. Plasma homocysteine levels were significantly higher in the WCH group compared to the controls (12.32 +/- 1.07 versus 5.35 +/- 1.38 micromol/L; P < 0.001) and the WCH group had significantly lower homocysteine values than the hypertensives (19.03 +/- 0.76 micromol/L P < 0.001). Total cholesterol and tri-glycerides were not different among the groups. There were no statistically significant differences in urinary albumin excretion (UAE) or creatinine clearance between the three groups. Hypertensive retinopathy was observed in the WCH group, but was less severe and less frequent compared to HTs. LVMI was greater in the WCH group compared to the NTs, but significantly less than HTs. The data demonstrate that WCH is associated with high levels of homocysteine. The increase in homocysteine level in WCH is not as high as in SHT. Since an elevated plasma homocysteine level is a strong risk factor for coronary artery disease and there was target organ damage in our WCH group, we conclude that WCH should not be considered to be an innocent trait.
The association between homocysteine and sustained hypertension (HT) has been studied. The aim of this study was to assess homocysteine levels in white coat hypertension (WCH) as an indicator of increased risk in the development of cardiovascular diseases. WCH was defined as clinical hypertension and a daytime ambulatory blood pressure of < 135/85 mmHg. Plasma levels of homocysteine were determined in patients with WCH, hypertension, and normotension (NT). The study group included 100 subjects, 33 with WCH (16 males, 17 females) aged 49.1 ± 1.9; 35 sustained hypertensives (17 males,18 females) aged 48.5 ± 1.7 and 32 normotensive control subjects (15 males, 17 females) aged 48.8 ± 2.2. The subjects were matched for age, gender, and body mass index. Patients with a smoking habit, dyslipidemia, or diabetes mellitus were not included in the study. Homocysteine levels were analyzed by ELISA. Plasma homocysteine levels were significantly higher in the WCH group compared to the controls (12.32 ± 1.07 versus 5.35 ± 1.38 μmol/L; P < 0.001) and the WCH group had significantly lower homocysteine values than the hypertensives (19.03 ± 0.76 μmol/L P < 0.001). Total cholesterol and tri-glycerides were not different among the groups. There were no statistically significant differences in urinary albumin excretion (UAE) or creatinine clearence between the three groups. Hypertensive retinopathy was observed in the WCH group, but was less severe and less frequent compared to HTs. LVMI was greater in the WCH group compared to the NTs, but significantly less than HTs. The data demonstrate that WCH is associated with high levels of homocysteine. The increase in homocysteine level in WCH is not as high as in SHT. Since an elevated plasma homocysteine level is a strong risk factor for coronary artery disease and there was target organ damage in our WCH group, we conclude that WCH should not be considered to be an innocent trait.
The association between homocysteine and sustained hypertension (HT) has been studied. The aim of this study was to assess homocysteine levels in white coat hypertension (WCH) as an indicator of increased risk in the development of cardiovascular diseases. WCH was defined as clinical hypertension and a daytime ambulatory blood pressure of < 135/85 mmHg. Plasma levels of homocysteine were determined in patients with WCH, hypertension, and normotension (NT). The study group included 100 subjects, 33 with WCH (16 males, 17 females) aged 49.1 +/- 1.9; 35 sustained hypertensives (17 males,18 females) aged 48.5 +/- 1.7 and 32 normotensive control subjects (15 males, 17 females) aged 48.8 +/- 2.2. The subjects were matched for age, gender, and body mass index. Patients with a smoking habit, dyslipidemia, or diabetes mellitus were not included in the study. Homocysteine levels were analyzed by ELISA. Plasma homocysteine levels were significantly higher in the WCH group compared to the controls (12.32 +/- 1.07 versus 5.35 +/- 1.38 micromol/L; P < 0.001) and the WCH group had significantly lower homocysteine values than the hypertensives (19.03 +/- 0.76 micromol/L P < 0.001). Total cholesterol and tri-glycerides were not different among the groups. There were no statistically significant differences in urinary albumin excretion (UAE) or creatinine clearance between the three groups. Hypertensive retinopathy was observed in the WCH group, but was less severe and less frequent compared to HTs. LVMI was greater in the WCH group compared to the NTs, but significantly less than HTs. The data demonstrate that WCH is associated with high levels of homocysteine. The increase in homocysteine level in WCH is not as high as in SHT. Since an elevated plasma homocysteine level is a strong risk factor for coronary artery disease and there was target organ damage in our WCH group, we conclude that WCH should not be considered to be an innocent trait.The association between homocysteine and sustained hypertension (HT) has been studied. The aim of this study was to assess homocysteine levels in white coat hypertension (WCH) as an indicator of increased risk in the development of cardiovascular diseases. WCH was defined as clinical hypertension and a daytime ambulatory blood pressure of < 135/85 mmHg. Plasma levels of homocysteine were determined in patients with WCH, hypertension, and normotension (NT). The study group included 100 subjects, 33 with WCH (16 males, 17 females) aged 49.1 +/- 1.9; 35 sustained hypertensives (17 males,18 females) aged 48.5 +/- 1.7 and 32 normotensive control subjects (15 males, 17 females) aged 48.8 +/- 2.2. The subjects were matched for age, gender, and body mass index. Patients with a smoking habit, dyslipidemia, or diabetes mellitus were not included in the study. Homocysteine levels were analyzed by ELISA. Plasma homocysteine levels were significantly higher in the WCH group compared to the controls (12.32 +/- 1.07 versus 5.35 +/- 1.38 micromol/L; P < 0.001) and the WCH group had significantly lower homocysteine values than the hypertensives (19.03 +/- 0.76 micromol/L P < 0.001). Total cholesterol and tri-glycerides were not different among the groups. There were no statistically significant differences in urinary albumin excretion (UAE) or creatinine clearance between the three groups. Hypertensive retinopathy was observed in the WCH group, but was less severe and less frequent compared to HTs. LVMI was greater in the WCH group compared to the NTs, but significantly less than HTs. The data demonstrate that WCH is associated with high levels of homocysteine. The increase in homocysteine level in WCH is not as high as in SHT. Since an elevated plasma homocysteine level is a strong risk factor for coronary artery disease and there was target organ damage in our WCH group, we conclude that WCH should not be considered to be an innocent trait.
Author Ertürk, Nurver
Simsek, Gönül
Kutlu, Ayse
Karter, Yesari
Öztürk, Esin
Uzun, Hafize
Çurgunlu, Asll
Erdine, Serap
Vehid, Suphi
Aydin, Seval
Author_xml – sequence: 1
  fullname: Çurgunlu, Asll
  organization: Department of Internal Medicine, Taksim Public Hospital
– sequence: 1
  fullname: Aydin, Seval
  organization: Department of Biochemistry, Taksim Public Hospital
– sequence: 1
  fullname: Ertürk, Nurver
  organization: Department of Family Medicine, Taksim Public Hospital
– sequence: 1
  fullname: Vehid, Suphi
  organization: Department of Public Health, Taksim Public Hospital
– sequence: 1
  fullname: Uzun, Hafize
  organization: Department of Biochemistry, Taksim Public Hospital
– sequence: 1
  fullname: Karter, Yesari
  organization: Department of Internal Medicine, Taksim Public Hospital
– sequence: 1
  fullname: Kutlu, Ayse
  organization: Department of Neurology, Taksim Public Hospital
– sequence: 1
  fullname: Erdine, Serap
  organization: Cardiology Institute, Cerrahpasa Medical Faculty, Istanbul University
– sequence: 1
  fullname: Simsek, Gönül
  organization: Department of Physiology, Cerrahpasa Medical Faculty
– sequence: 1
  fullname: Öztürk, Esin
  organization: Department of Internal Medicine, Taksim Public Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/15876808$$D View this record in MEDLINE/PubMed
BookMark eNpt0EtLAzEUBeAgFfvQjbh26UKYmsl7ViJFrVBwo-uQZO7YlHnUJF303zsytYK4SQL5zoV7pmjUdi0gdJnjec6puPPrzZyJOWH8BE1yyoqMkqIYHd6ECj5G0xg3GLOcY3mGxjlXUiisJuhqud9CWHdN5_YxgW-h8eYcnVamjnBxuGfo_enxbbHMVq_PL4uHVeYYISkDAjwvODZKMUpJVVJbcgmUAa0kpthiIFWhSuuExGXJqOTWcYdLC5Zga-gM3Qxzt6H73EFMuvHRQV2bFrpd1EIqnAumenh9gDvbQKm3wTcm7PXPHj24HYALXYwBql-C9XdJui9JM6H7knqM_2Dnk0m-a1Mwvv4_cj9ENjGZDzhONyF5V8ORDkefOP64tQkaWvoFHQZ_lA
CitedBy_id crossref_primary_10_2478_ahem_2021_0002
crossref_primary_10_1097_MBP_0000000000000171
crossref_primary_10_1536_ihj_49_671
crossref_primary_10_1038_sj_jhh_1002325
crossref_primary_10_1536_ihj_49_87
crossref_primary_10_1536_ihj_48_605
crossref_primary_10_2169_internalmedicine_47_0787
crossref_primary_10_1097_HJH_0000000000000416
crossref_primary_10_1080_10641960802251958
crossref_primary_10_1111_1440_1681_12114
crossref_primary_10_1017_S0029665109991728
crossref_primary_10_1111_j_1440_1681_2008_04886_x
crossref_primary_10_1007_s11010_007_9434_5
crossref_primary_10_3109_08037051_2011_575577
crossref_primary_10_1536_ihj_49_449
crossref_primary_10_1097_MD_0000000000016085
crossref_primary_10_1111_j_1742_1241_2006_00959_x
crossref_primary_10_5662_wjm_v4_i3_144
Cites_doi 10.1161/01.CIR.90.5.2291
10.1038/sj.jhh.1000917
10.1016/S0735-1097(01)01492-9
10.1016/S0735-1097(02)01717-5
10.1161/01.HYP.16.6.617
10.1038/sj.jhh.1001524
10.1161/01.CIR.96.6.1745
10.1001/jama.274.19.1526
10.1161/01.CIR.0000019737.87850.5A
10.1016/0002-9149(86)90771-X
10.1161/01.HYP.0000101690.58391.13
10.1161/01.HYP.24.1.101
10.1055/s-2000-8096
10.1016/S0161-6420(82)34664-3
10.1515/CCLM.2003.216
10.1136/bmj.322.7285.531
10.1016/0021-9150(89)90118-4
10.1001/jama.261.6.873
10.1016/S0895-7061(00)01321-2
10.1161/01.HYP.21.6.836
10.1001/jama.1988.03720020027031
10.1093/ajh/5.4.207
10.1136/bmj.320.7242.1128
10.1016/S0895-7061(02)02984-9
10.1093/aje/kwf157
10.1055/s-2000-8472
10.1016/0895-7061(96)00203-8
10.1177/0091270003258190
10.1007/s003950070012
ContentType Journal Article
Copyright 2005 by the International Heart Journal Association
Copyright_xml – notice: 2005 by the International Heart Journal Association
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1536/ihj.46.245
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1349-3299
EndPage 254
ExternalDocumentID 15876808
10_1536_ihj_46_245
article_ihj_46_2_46_2_245_article_char_en
Genre Journal Article
GroupedDBID ---
.55
29J
2WC
3O-
53G
5GY
AAFWJ
ACPRK
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
GX1
JSF
JSH
KQ8
OK1
RJT
RZJ
SDH
TKC
TR2
X7M
ZXP
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c422t-e2e51950a884332fd3bd57e34e3f7030b0e2f98dbc670dd4375bc5c0dbeb20ba3
ISSN 1349-2365
IngestDate Fri Jul 11 05:03:13 EDT 2025
Thu May 23 23:10:33 EDT 2024
Tue Jul 01 00:55:59 EDT 2025
Thu Apr 24 23:01:28 EDT 2025
Wed Sep 03 06:18:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c422t-e2e51950a884332fd3bd57e34e3f7030b0e2f98dbc670dd4375bc5c0dbeb20ba3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.jstage.jst.go.jp/article/ihj/46/2/46_2_245/_article/-char/en
PMID 15876808
PQID 67801648
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_67801648
pubmed_primary_15876808
crossref_primary_10_1536_ihj_46_245
crossref_citationtrail_10_1536_ihj_46_245
jstage_primary_article_ihj_46_2_46_2_245_article_char_en
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2005-03-01
PublicationDateYYYYMMDD 2005-03-01
PublicationDate_xml – month: 03
  year: 2005
  text: 2005-03-01
  day: 01
PublicationDecade 2000
PublicationPlace Japan
PublicationPlace_xml – name: Japan
PublicationTitle International Heart Journal
PublicationTitleAlternate Int. Heart J.
PublicationYear 2005
Publisher International Heart Journal Association
Publisher_xml – name: International Heart Journal Association
References 19. Ramsay L, Williams B, Johnston G, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-92. (Review)
28. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G. Homocysteine and essential hypertension. J Clin Pharmacol 2003; 43: 1299-306. (Review)
5. Hoegholm A, Bang LE, Kristensen KS, Nielsen JW, Holm J. Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. Hypertension 1994; 24: 101-5.
23. Walsh JB. Hypertensive retinopathy. Description, classification, and prognosis. Ophthalmology 1982; 89: 1127-31.
13. van Guldener C, Stehouwer CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Tromb Hemost 2000; 26: 281-9. (Review)
12. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274: 1526-33.
27. Boers GH. Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease. Semin Thromb Hemost 2000; 26: 291-5. (Review)
20. Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.
4. Cardillo C, De Felice F, Campia U, Folli G. Psychological reactivity and cardiac end-organ changes in white coat hypertension. Hypertension 1993; 21: 836-44.
25. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left venticular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-8.
16. Lip GY, Edmunds E, Martin SC, Jones AF, Blann AD, Beevers DG. A pilot study of homocyst(e)ine levels in essential hypertension: relationship to von Willebrand factor, an index of endothelial damage. Am J Hypertens 2001; 14: 627-31.
33. Kahleova R, Palyzova D, Zvara K, et al. Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins. Am J Hypertens 2002; 15: 857-64.
9. Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002; 156: 1105-13.
2. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA 1988; 259: 225-8.
26. Sainani GS, Sainani R. Homocysteine and its role in the pathogenesis of atherosclerotic vascular disease. J Assoc Physicians India 2002; 50 (Suppl): 5-8.
14. Virdis A, Ghiadoni L, Cardinal H, et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocysteinemia in normotensive subjects and patients with essential hypertension. J Am Coll Cardiol 2001; 38: 1106-15.
24. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020-5.
22. O'Brien E, Coats A, Owens P, et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ 2000; 320: 1128-34. (Review)
30. Stehouwer CD, van Guldener C. Does homocysteine cause hypertension? Clin Chem Lab Med 2003; 41: 1408-11. (Review)
3. White WB, Schulman P, McCabe EJ, Dey HM. Average daily blood pressure, not office blood pressure, determines cardiac function in patients with hypertension. JAMA 1989; 261: 873-7.
10. Araki A, Sako Y, Fukusimma Y, Matsumoto M, Asada T, Kita T. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 1989; 79: 139-46.
17. Pierdomenico SD, Bucci A, Lapenna D, et al. Circulating homocysteine levels in sustained and white coat hypertension. J Hum Hypertens 2003; 17: 165-70.
6. Bjorklund K, Lind L, Vessby B, Andren B, Lithell H. Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period: a population-based study of elderly men. Circulation 2002; 106: 63-8.
1. Soma J, Aakhus S, Dahl K, et al. Hemodynamics in white coat hypertension compared to ambulatory hypertension and normotension. Am J Hypertens 1996; 9: 1090-8.
11. Sutton-Tyrrell K, Bostom A, Sefhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997; 96: 1745-9.
21. O'Brien E, Waeber B, Parati G, Staessen J, Myers MJ. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001; 322: 531-6.
29. Sundstrom J, Sullivan L, D'Agostino RB, et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study. Hypertension 2003; 42: 1100-5.
34. Bjorklund K, Lind L, Vessby B, Andren B, Lithell H. Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period: a population-based study of elderly men. Circulation 2002; 106: 63-8.
31. Pierdomenico SD, Bucci A, Lapenna D, et al. Circulating homocysteine levels in sustained and white coat hypertension. J Hum Hypertens 2003; 17: 165-70.
8. Weber MA, Neutel JM, Smith DH, Graettinger WF. Diagnosis of mild hypertension by ambulatory blood pressure monitoring. Circulation 1994; 90: 2291-8.
15. Maxwell SR. Coronary artery disease-free radical damage, antioxidant protection and the role of homocysteine. Basic Res Cardiol 2000; 95 Suppl 1: 165-71.
32. Brunelli T, Pepe G, Marcucci R, et al. Comparison of three methods for total homocysteine plasma determination. Clin Lab 2001; 47: 393-7.
7. Julius S, Mejia A, Jones K, et al. ‘White coat’ versus ‘sustained’ borderline hypertension in Tecumseh, Michigan. Hypertension 1990; 16: 617-23.
18. American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens 1992; 5: 207-9.
23
24
25
26
27
28
29
(22) 1982; 89
(7) 1994; 90
(9) 1989; 79
30
31
10
32
11
33
12
13
14
15
16
17
18
19
(5) 1994; 24
1
3
8
(2) 1988; 259
(4) 1993; 21
20
(6) 1990; 16
21
References_xml – reference: 12. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274: 1526-33.
– reference: 21. O'Brien E, Waeber B, Parati G, Staessen J, Myers MJ. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001; 322: 531-6.
– reference: 7. Julius S, Mejia A, Jones K, et al. ‘White coat’ versus ‘sustained’ borderline hypertension in Tecumseh, Michigan. Hypertension 1990; 16: 617-23.
– reference: 18. American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens 1992; 5: 207-9.
– reference: 3. White WB, Schulman P, McCabe EJ, Dey HM. Average daily blood pressure, not office blood pressure, determines cardiac function in patients with hypertension. JAMA 1989; 261: 873-7.
– reference: 6. Bjorklund K, Lind L, Vessby B, Andren B, Lithell H. Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period: a population-based study of elderly men. Circulation 2002; 106: 63-8.
– reference: 2. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA 1988; 259: 225-8.
– reference: 31. Pierdomenico SD, Bucci A, Lapenna D, et al. Circulating homocysteine levels in sustained and white coat hypertension. J Hum Hypertens 2003; 17: 165-70.
– reference: 33. Kahleova R, Palyzova D, Zvara K, et al. Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins. Am J Hypertens 2002; 15: 857-64.
– reference: 23. Walsh JB. Hypertensive retinopathy. Description, classification, and prognosis. Ophthalmology 1982; 89: 1127-31.
– reference: 26. Sainani GS, Sainani R. Homocysteine and its role in the pathogenesis of atherosclerotic vascular disease. J Assoc Physicians India 2002; 50 (Suppl): 5-8.
– reference: 4. Cardillo C, De Felice F, Campia U, Folli G. Psychological reactivity and cardiac end-organ changes in white coat hypertension. Hypertension 1993; 21: 836-44.
– reference: 27. Boers GH. Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease. Semin Thromb Hemost 2000; 26: 291-5. (Review)
– reference: 15. Maxwell SR. Coronary artery disease-free radical damage, antioxidant protection and the role of homocysteine. Basic Res Cardiol 2000; 95 Suppl 1: 165-71.
– reference: 29. Sundstrom J, Sullivan L, D'Agostino RB, et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study. Hypertension 2003; 42: 1100-5.
– reference: 5. Hoegholm A, Bang LE, Kristensen KS, Nielsen JW, Holm J. Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. Hypertension 1994; 24: 101-5.
– reference: 14. Virdis A, Ghiadoni L, Cardinal H, et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocysteinemia in normotensive subjects and patients with essential hypertension. J Am Coll Cardiol 2001; 38: 1106-15.
– reference: 19. Ramsay L, Williams B, Johnston G, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-92. (Review)
– reference: 22. O'Brien E, Coats A, Owens P, et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ 2000; 320: 1128-34. (Review)
– reference: 17. Pierdomenico SD, Bucci A, Lapenna D, et al. Circulating homocysteine levels in sustained and white coat hypertension. J Hum Hypertens 2003; 17: 165-70.
– reference: 32. Brunelli T, Pepe G, Marcucci R, et al. Comparison of three methods for total homocysteine plasma determination. Clin Lab 2001; 47: 393-7.
– reference: 30. Stehouwer CD, van Guldener C. Does homocysteine cause hypertension? Clin Chem Lab Med 2003; 41: 1408-11. (Review)
– reference: 25. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left venticular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-8.
– reference: 16. Lip GY, Edmunds E, Martin SC, Jones AF, Blann AD, Beevers DG. A pilot study of homocyst(e)ine levels in essential hypertension: relationship to von Willebrand factor, an index of endothelial damage. Am J Hypertens 2001; 14: 627-31.
– reference: 24. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020-5.
– reference: 11. Sutton-Tyrrell K, Bostom A, Sefhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997; 96: 1745-9.
– reference: 13. van Guldener C, Stehouwer CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Tromb Hemost 2000; 26: 281-9. (Review)
– reference: 1. Soma J, Aakhus S, Dahl K, et al. Hemodynamics in white coat hypertension compared to ambulatory hypertension and normotension. Am J Hypertens 1996; 9: 1090-8.
– reference: 34. Bjorklund K, Lind L, Vessby B, Andren B, Lithell H. Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period: a population-based study of elderly men. Circulation 2002; 106: 63-8.
– reference: 8. Weber MA, Neutel JM, Smith DH, Graettinger WF. Diagnosis of mild hypertension by ambulatory blood pressure monitoring. Circulation 1994; 90: 2291-8.
– reference: 10. Araki A, Sako Y, Fukusimma Y, Matsumoto M, Asada T, Kita T. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 1989; 79: 139-46.
– reference: 20. Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.
– reference: 28. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G. Homocysteine and essential hypertension. J Clin Pharmacol 2003; 43: 1299-306. (Review)
– reference: 9. Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002; 156: 1105-13.
– volume: 90
  start-page: 2291
  issn: 0009-7322
  year: 1994
  ident: 7
  publication-title: Circulation
  doi: 10.1161/01.CIR.90.5.2291
– ident: 18
  doi: 10.1038/sj.jhh.1000917
– ident: 13
  doi: 10.1016/S0735-1097(01)01492-9
– ident: 23
  doi: 10.1016/S0735-1097(02)01717-5
– volume: 16
  start-page: 617
  issn: 0194-911X
  year: 1990
  ident: 6
  publication-title: Hypertension
  doi: 10.1161/01.HYP.16.6.617
– ident: 30
  doi: 10.1038/sj.jhh.1001524
– ident: 10
  doi: 10.1161/01.CIR.96.6.1745
– ident: 11
  doi: 10.1001/jama.274.19.1526
– ident: 33
  doi: 10.1161/01.CIR.0000019737.87850.5A
– ident: 31
– ident: 24
  doi: 10.1016/0002-9149(86)90771-X
– ident: 28
  doi: 10.1161/01.HYP.0000101690.58391.13
– volume: 24
  start-page: 101
  issn: 0194-911X
  year: 1994
  ident: 5
  publication-title: Hypertension
  doi: 10.1161/01.HYP.24.1.101
– ident: 26
  doi: 10.1055/s-2000-8096
– volume: 89
  start-page: 1127
  issn: 0161-6420
  year: 1982
  ident: 22
  publication-title: Ophthalmology
  doi: 10.1016/S0161-6420(82)34664-3
– ident: 29
  doi: 10.1515/CCLM.2003.216
– ident: 20
  doi: 10.1136/bmj.322.7285.531
– volume: 79
  start-page: 139
  issn: 0021-9150
  year: 1989
  ident: 9
  publication-title: Atherosclerosis
  doi: 10.1016/0021-9150(89)90118-4
– ident: 3
  doi: 10.1001/jama.261.6.873
– ident: 15
  doi: 10.1016/S0895-7061(00)01321-2
– volume: 21
  start-page: 836
  issn: 0194-911X
  year: 1993
  ident: 4
  publication-title: Hypertension
  doi: 10.1161/01.HYP.21.6.836
– volume: 259
  start-page: 225
  issn: 0098-7484
  year: 1988
  ident: 2
  publication-title: JAMA The Journal of the American Medical Association
  doi: 10.1001/jama.1988.03720020027031
– ident: 17
  doi: 10.1093/ajh/5.4.207
– ident: 19
– ident: 21
  doi: 10.1136/bmj.320.7242.1128
– ident: 32
  doi: 10.1016/S0895-7061(02)02984-9
– ident: 8
  doi: 10.1093/aje/kwf157
– ident: 12
  doi: 10.1055/s-2000-8472
– ident: 1
  doi: 10.1016/0895-7061(96)00203-8
– ident: 27
  doi: 10.1177/0091270003258190
– ident: 14
  doi: 10.1007/s003950070012
– ident: 16
  doi: 10.1038/sj.jhh.1001524
– ident: 25
SSID ssj0041507
Score 1.7445872
Snippet The association between homocysteine and sustained hypertension (HT) has been studied. The aim of this study was to assess homocysteine levels in white coat...
SourceID proquest
pubmed
crossref
jstage
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 245
SubjectTerms Blood Pressure Monitoring, Ambulatory
Body Mass Index
Coronary Artery Disease - complications
Endothelium, Vascular - pathology
Female
Homocysteine
Homocysteine - blood
Humans
Hyperhomocysteinemia - complications
Hypertension - etiology
Male
Middle Aged
Office Visits
Retinal Diseases - etiology
Risk Factors
Smoking
Target organ damage
White coat hypertension
Subtitle An Additional Risk Factor in White Coat Hypertension
Title Hyperhomocysteinemia
URI https://www.jstage.jst.go.jp/article/ihj/46/2/46_2_245/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/15876808
https://www.proquest.com/docview/67801648
Volume 46
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX International Heart Journal, 2005, Vol.46(2), pp.245-254
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagIMSlAspjy6sSXBDKNms7sfeIqsIKVC50pb1FfqXdaptFu8mB_fWMH3GydJEKFytyZvKYscczfnyD0Hs20nluzCixi2oJ5WKcSMVMokoYu0cG-oiy85Bn3_PJlH6dZbM2V3s4XVLLodrsPFfyP1qFOtCrPSX7D5qND4UKuAb9QgkahvJWOp5AELm6XF4vlcVjBn_xei763ub2dJ_NXV1_7D8YBG0XyjlrVhdNtWicoVgv4s1vbsOns9JmDUF1Wz_dNM5YTUQ533Rt5pf2gAQ_LIT41nRC1u2nChaQ0HGCiU_gMDRdHcE-k1FrNsPM4bwXvQYbSLPecIo9RvQNS525VDLzy6shzYeRpQ-H_ccwFTcP2rAFuAvgLWheAO9ddA8z5lbpv8ziDh9qfV0Xb4c_Cui0wHvcvXfLH7l_BS75hfl7tOG8jvNHaD-EC0efvO4fozumeoIenIUNEQfoYFcTeIqmn0_PTyZJSHSRKIpxnRhsLMhPKji3cHKlJlJnzBBqSGktskwNLsdcS5WzVGtKWCZVplItjcSpFOQZ2quWlXmBjoSkuZJSslwQyqjiWqSEC04l1SOl9AB9aH-3UAEF3iYjWRQ3xTpA7yLtT499spOKe6lFmtAfIo0vgDTesScKoQMP0NtWzgVYNbtUJSqzbNYFuFAW-40P0HMv_u4DMhi_ecoPb_VxL9HDrpG_Qnv1qjGvwYus5RvXVn4DTjByaA
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hyperhomocysteinemia&rft.jtitle=International+heart+journal&rft.au=%C3%87urgunlu%2C+Asll&rft.au=Karter%2C+Yesari&rft.au=Uzun%2C+Hafize&rft.au=Aydin%2C+Seval&rft.date=2005-03-01&rft.issn=1349-2365&rft.eissn=1349-3299&rft.volume=46&rft.issue=2&rft.spage=245&rft.epage=254&rft_id=info:doi/10.1536%2Fihj.46.245&rft.externalDBID=n%2Fa&rft.externalDocID=10_1536_ihj_46_245
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1349-2365&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1349-2365&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1349-2365&client=summon